Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study
A HFrEF polypill-based strategy was viewed as highly acceptable, appropriate, and feasible by patients and physicians. Participants described key priorities in HFrEF polypill design, titratability, and potential impacts on health equity that will directly inform future randomized controlled trials.
Authors
- Matthew S. Durstenfeld (ORCID: https://orcid.org/0000-0002-7612-3352)
- Colette DeJong (ORCID: https://orcid.org/0000-0003-0514-3193)
- Priscilla Y. Hsue (ORCID: https://orcid.org/0000-0002-3427-6043)
- Mark D. Huffman (ORCID: https://orcid.org/0000-0001-7412-2519)
- Mansi Agarwal (ORCID: https://orcid.org/0000-0002-0367-7733)
- Anubha Agarwal (ORCID: https://orcid.org/0000-0002-7090-5601)
- Virginia McKay (ORCID: https://orcid.org/0000-0002-9299-3294)
- Amaris M. Hairston
- Justin C. Chen (ORCID: https://orcid.org/0000-0001-6858-7686)
Institutions
- University of California, Los Angeles (US)
- Palo Alto University (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- VA Palo Alto Health Care System (US)
- The George Institute for Global Health (AU)
- Stanford Medicine (US)
- University of Missouri (US)
- Stanford University (US)
Publication Details
- Journal
- Circulation Cardiovascular Quality and Outcomes
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1161/circoutcomes.124.011121
- Citations
- 4
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Washington University in St. Louis
- World Heart Federation
- George Institute for Global Health
- National Institutes of Health
- University of California, San Francisco
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences